business
AstraZeneca stock falls after FDA panel votes against new cancer drug
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- Shares of Astra Zeneca turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug.
- Food and Drug Administration late Thursday voted 6-3 against Astra Zeneca's oral drug camizestrant intended for the treatment of a type of breast cancer tumor, citing concerns around trial design.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
Shares of Astra Zeneca turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug.
An advisory panel for the U.S. Food and Drug Administration late Thursday voted 6-3 against Astra Zeneca's oral drug camizestrant intended for the treatment of a type of breast cancer tumor, citing concerns around trial design.
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop